3 ms·
> In 2030, would we as a society rather have a generic, cheap, openly available HepC cure or not? That is the question you need to ask, and I don't think anyone
by DanBC 9y ago
> In 2030, would we as a society rather have a generic, cheap, openly available HepC cure or not? That is the question you need to ask, and I don't think anyone would say no to that. The $84K drug will fall off patent by then, which means the system we currently have, flawed as it is, will produce that outcome.
I think if we look at the shenanigans around Avastin and Lucentis we'll see that patents and drug companies don't always work in the public interest.
http://www.bbc.co.uk/news/health-30138097 http://www.bbc.co.uk/news/health-30138097